Dr Reddy's Laboratories EBIT 2010-2024 | RDY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Dr Reddy's Laboratories 2024 EBIT was 0.812B, a 16.83% increase from 2023.
Dr Reddy's Laboratories 2023 EBIT was 0.695B, a 78.66% increase from 2022.
Dr Reddy's Laboratories 2022 EBIT was 0.389B, a 13.36% decline from 2021.

EBIT can be defined as earnings before interest and taxes.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Dr Reddy's Laboratories 2024 EBIT was 0.812B, a 16.83% increase from 2023.
Dr Reddy's Laboratories 2023 EBIT was 0.695B, a 78.66% increase from 2022.
Dr Reddy's Laboratories 2022 EBIT was 0.389B, a 13.36% decline from 2021.

EBIT can be defined as earnings before interest and taxes.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$20.1B
BridgeBio Pharma (BBIO)	$5B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.4B
Supernus Pharmaceuticals (SUPN)	$1.8B
Taysha Gene Therapies (TSHA)	$449M
Personalis (PSNL)	$315M
Assembly Biosciences (ASMB)	$117M
Acasti Pharma (ACST)	$28M
Sol-Gel Technologies (SLGL)	$20M
Evoke Pharma (EVOK)	$4M
Teligent (TLGT)	$0M